A. Guzman-Perez

发表

Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.

Steve Schneider, Xin Huang, John Newcomb, 2013, Journal of medicinal chemistry.

A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo.

R. J. Hill, D. Flynn, D. Knight, 2001, The Journal of pharmacology and experimental therapeutics.

Discovery of 6-Oxo-4-Phenyl-Hexanoic Acid Derivatives as RORγt Inverse Agonists Showing Favorable ADME Profile.

S. Shuto, Keiko Kumazawa, Zhulun Wang, 2021, Bioorganic & medicinal chemistry letters.

Discovery of [1,2,4]Triazolo[1,5-a]pyridine Derivatives as Potent and Orally Bioavailable RORγt Inverse Agonists.

S. Shuto, Zhulun Wang, Xiaoshan Min, 2020, ACS medicinal chemistry letters.

Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists.

Daniel P. Walker, A. Kalgutkar, Joel Morris, 2009, Bioorganic & medicinal chemistry letters.

Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.

Dong Liu, R. Fremeau, H. Bregman, 2016, Journal of medicinal chemistry.

Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity.

Stephanie D. Geuns-Meyer, N. Gavva, Y. Teffera, 2016, Journal of medicinal chemistry.

Exploring Aromatic Chemical Space with NEAT: Novel and Electronically Equivalent Aromatic Template

Brajesh K. Rai, Alan M. Mathiowetz, Meihua Tu, 2012, J. Chem. Inf. Model..

The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.

Michael D. Hamilton, J. Pfefferkorn, N. Barucci, 2012, Bioorganic & medicinal chemistry letters.

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

M. Ammirati, J. Treadway, S. Liras, 2011 .

Correction to Analyzing Learned Molecular Representations for Property Prediction

Regina Barzilay, Tommi Jaakkola, Connor W. Coley, 2019, J. Chem. Inf. Model..

Structure–pharmacokinetic relationship of in vivo rat biliary excretion

Dong Li, Yue Chen, A. Guzman-Perez, 2010, Biopharmaceutics & drug disposition.

Optimizing glucokinase activator binding kinetics to lower in vivo hypoglycemia risk

T. Rolph, J. Pfefferkorn, K. Borzilleri, 2014 .

Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis

V. Paralkar, L. Buckbinder, J. Kath, 2007, Proceedings of the National Academy of Sciences.

Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1).

A. Fossa, D. Knight, A. Guzman-Perez, 2006, Cardiovascular drug reviews.

Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core.

M. Munchhof, J. Litchfield, K. Karki, 2011, Bioorganic & medicinal chemistry letters.

Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors.

Jacquelyn L. Klug-McLeod, Daniel P. Walker, David A. Price, 2012, Bioorganic & medicinal chemistry letters.

The discovery of benzoxazine sulfonamide inhibitors of NaV1.7: Tools that bridge efficacy and target engagement.

R. Fremeau, H. Bregman, M. Chu-Moyer, 2017, Bioorganic & medicinal chemistry letters.

Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.

R. J. Hill, D. Knight, A. Guzman-Perez, 2001, Bioorganic & medicinal chemistry letters.

The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.

J. Treadway, J. Pfefferkorn, W. Zavadoski, 2013, Bioorganic & medicinal chemistry letters.

Small molecule inhibitors of the Pyk2 and FAK kinases modulate chemoattractant-induced migration, adhesion and Akt activation in follicular and marginal zone B cells.

Kathy W. K. Tse, M. Gold, L. Buckbinder, 2012, Cellular immunology.

Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.

H. Bregman, J. Newcomb, P. Andrews, 2013, Journal of medicinal chemistry.

The Catalytic Enantioselective Construction of Molecules with Quaternary Carbon Stereocenters.

E. Corey, A. Guzman-Perez, 1998, Angewandte Chemie.

A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.

S. Wright, J. Pfefferkorn, J. Litchfield, 2012, Bioorganic & medicinal chemistry letters.

Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors.

Steve Schneider, Xin Huang, Angel Guzman-Perez, 2013, ACS medicinal chemistry letters.

Kinetic Resolution by Enantioselective Dihydroxylation of Secondary Allylic 4-Methoxybenzoate Esters Using a Mechanistically Designed Cinchona Alkaloid Catalyst

E. Corey, A. Guzman-Perez, M. C. Noe, 1995 .

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.

R. Fremeau, H. Bregman, M. Chu-Moyer, 2017, Journal of Medicinal Chemistry.

Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity.

Li Xing, Leonard Buckbinder, Amy Baumann, 2009, Bioorganic & medicinal chemistry letters.

A New Total Synthesis of Withasomnine

A. Guzman-Perez, L. A. Maldonado, 1991 .

Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase.

Eliot Sugarman, Zhengrong Zhao, Wei Song, 2012, Journal of medicinal chemistry.

Demonstration of the Synthetic Power of Oxazaborolidine-Catalyzed Enantioselective Diels-Alder Reactions by Very Efficient Routes to Cassiol and Gibberellic Acid

E. Corey, T. Loh, A. Guzman-Perez, 1994 .

HIGHLY ENANTIOSELECTIVE AND REGIOSELECTIVE CATALYTIC DIHYDROXYLATION OF HOMOALLYLIC ALCOHOL DERIVATIVES

E. Corey, A. Guzman-Perez, M. C. Noe, 1995 .

The enantiospecific Nicholas reaction

A. Guzman-Perez, A. Kluge, A. Muehldorf, 1994 .

The application of a mechanistic model leads to the extension of the Sharpless asymmetric dihydroxylation to allylic 4-methoxybenzoates and conformationally related amine and homoallylic alcohol derivatives.

E. Corey, A. Guzman-Perez, M. C. Noe, 1995 .

Catalytic enantioselective synthesis of (14R)-14-hydroxy-4,14-retro-retinol from retinyl acetate

E. Corey, A. Guzman-Perez, M. C. Noe, 1995 .

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.

Roman Shimanovich, Angel Guzman-Perez, R. Fremeau, 2017, Journal of medicinal chemistry.

Analyzing Learned Molecular Representations for Property Prediction

Regina Barzilay, Tommi Jaakkola, Connor W. Coley, 2019, J. Chem. Inf. Model..

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.

Leonard Buckbinder, Jacquelyn Klug-McLeod, Angel Guzman-Perez, 2008, Bioorganic & medicinal chemistry letters.

Applications of parallel synthetic lead hopping and pharmacophore-based virtual screening in the discovery of efficient glycine receptor potentiators.

H. Bregman, L. Berry, Liyue Huang, 2017, European journal of medicinal chemistry.

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.

Eliot Sugarman, Angel Guzman-Perez, G. S. Walker, 2011, ACS medicinal chemistry letters.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.

Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif.

K. Gajiwala, M. Hickey, J. Pfefferkorn, 2013, Bioorganic & medicinal chemistry letters.

Optimization of triazole -based TGR5 agonists towards orally available agents

Bryan M. Li, J. Warmus, D. Hepworth, 2013 .

Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.

Angel Guzman-Perez, Dawn Mather, W. Zavadoski, 2013, Bioorganic & medicinal chemistry.

The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine Receptors.

H. Bregman, Xin Huang, Liyue Huang, 2017, Journal of medicinal chemistry.

Functionalization of aromatic amino acids via direct C-H activation: generation of versatile building blocks for accessing novel peptide space.

K. James, S. Liras, A. Guzman-Perez, 2010, Organic letters.

Are Learned Molecular Representations Ready For Prime Time? pdf

Regina Barzilay, Tommi S. Jaakkola, Wengong Jin, 2019, ArXiv.

The Catalytic Enantioselective Construction of Molecules with Quaternary Carbon Stereocenters

E. Corey, A. Guzman-Perez, 1998 .

Identification of a novel conformationally constrained glucagon receptor antagonist.

S. Wright, A. Kalgutkar, J. Pfefferkorn, 2014, Bioorganic & medicinal chemistry letters.

Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis.

Daniel P. Walker, J. Bauman, A. Kalgutkar, 2010, Chemical research in toxicology.

Allylic 4-methoxybenzoates display excellent reagent-controlled double diastereoselection in the sharpless asymmetric dihydroxylation: Application to highly selective total syntheses of polyols

E. Corey, A. Guzman-Perez, 1997 .

Building structure-activity insights through patent mining.

Kevin J Filipski, Meihua Tu, Jeffrey A Pfefferkorn, 2012, Pharmaceutical patent analyst.

Short Enantioselective Synthesis of (-)-Ovalicin, a Potent Inhibitor of Angiogenesis, Using Substrate-Enhanced Catalytic Asymmetric Dihydroxylation

E. Corey, A. Guzman-Perez, M. C. Noe, 1994 .

Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors.

B. Moyer, Nagasree Chakka, A. Guzman-Perez, 2017, Bioorganic & medicinal chemistry letters.

Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors.

A. Guzman-Perez, E. Dimauro, Violeta L Yu, 2017, MedChemComm.

Analyzing Learned Molecular Representations for Property Prediction

Connor W. Coley, T. Jaakkola, R. Barzilay, 2019, J. Chem. Inf. Model..

Increased building block access through collaboration.

Angel Guzman-Perez, Christopher J Helal, Alessandra Bartolozzi, 2018, Drug discovery today.

STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts

G. Kryukov, L. Buckbinder, E. Jackson, 2023, Cancer discovery.

Exploring Aromatic Chemical Space with NEAT: Novel and Electronically Equivalent Aromatic Template

A. Mathiowetz, S. Liras, M. Hayward, 2012, Journal of Chemical Information and Modeling.